Aplastic anemia is a rare but serious condition in which the bone marrow fails to produce enough blood cells, leaving patients at risk of severe infections, bleeding, and anemia. Most cases are caused by an autoimmune attack on blood stem cells, though some are inherited or triggered by drugs and toxins.
What's actually going on in research
Allogeneic stem cell transplantation from a matched sibling remains curative for younger patients with a suitable donor, but immunosuppressive therapy with horse antithymocyte globulin and cyclosporine is standard for those without a transplant option. Eltrombopag, a thrombopoietin receptor agonist, is now added to immunosuppression after trials showed it improves response rates. Trials are exploring alternative donors for transplant, novel immunosuppressive combinations, and gene therapy for inherited forms.
Enhanced immunosuppression
Adding eltrombopag to standard horse antithymocyte globulin and cyclosporine is now established as improving response rates, and trials are testing further additions such as eltanexor and other agents.
Alternative donor transplant
For patients lacking a matched sibling donor, trials are refining outcomes with haploidentical (half-matched) family donors and unrelated donors using improved conditioning and graft-versus-host disease prevention.
Gene therapy for inherited forms
Inherited aplastic anemias such as Fanconi anemia are being targeted with gene-correction strategies using CRISPR and viral vectors to restore hematopoietic stem cell function.
What to know before you search
Eligibility depends on disease severity, patient age, donor availability, prior treatment, and whether the cause is inherited or acquired.
What types of trials are currently open
- Immunosuppression trials — Testing new drug combinations to improve response rates in patients not eligible for stem cell transplantation.
- Stem cell transplant trials — Refining donor selection, conditioning regimens, and graft-versus-host disease prevention in transplant-eligible patients.
- Thrombopoietin agonist trials — Studying eltrombopag and related drugs as additions to standard immunosuppression.
- Gene therapy trials — Testing gene-correction approaches for inherited bone marrow failure syndromes.
- Supportive care trials — Evaluating transfusion strategies, infection prophylaxis, and iron chelation in aplastic anemia.
Recently added Aplastic Anemia trials
MRI as Noninvasive Innovative Approach in Detection and Monitoring of Malignant Oral Lesions in Fanconi Anemia Patients
This study being done to learn more about the use of medical Magnetic Resonance Imaging (mMRI) and dedicated dental MRI (ddMRI) as a non-invasive diagnosing tool when evaluating potential oral cancerous and precancerous lesions in Fanconi Anemia patients.
Complete brain imaging scans to understand how anemia affects thinking
Anemia is a global public health concern and is closely linked to dysfunction of brain cognitive neural networks, a key mechanism underlying cognitive impairment. Such deficits-including declines in memory, learning, processing speed, and executive function-reduce daily living abilities and increase risks of falls and depression. Functional near-infrared spectroscopy (fNIRS) enables real-time monitoring of oxygenated and deoxygenated hemoglobin fluctuations, reflecting brain network function. This study aims to identify affected neural network regions in anemic patients and visualize connectivity changes using heatmaps and arc-based mapping. The findings will support early detection of cognitive impairment and guide precise clinical interventions, ultimately informing individualized treatment strategies to enhance therapeutic outcomes and quality of life.
Find Aplastic Anemia trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.